Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis
Ashok N. Babu, … , Norbert F. Voelkel, Mark R. Nicolls
Ashok N. Babu, … , Norbert F. Voelkel, Mark R. Nicolls
Published December 3, 2007
Citation Information: J Clin Invest. 2007;117(12):3774-3785. https://doi.org/10.1172/JCI32311.
View: Text | PDF
Research Article

Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis

  • Text
  • PDF
Abstract

Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstacle to long-term survival following lung transplantation. Here, we show the importance of functional microvasculature in the prevention of epithelial loss and fibrosis due to rejection and for the first time, relate allograft microvascular injury and loss of tissue perfusion to immunotherapy-resistant rejection. To explore the role of alloimmune rejection and airway ischemia in the development of fibroproliferation, we used a murine orthotopic tracheal transplant model. We determined that transplants were reperfused by connection of recipient vessels to donor vessels at the surgical anastomosis site. Microcirculation through the newly formed vascular anastomoses appeared partially dependent on VEGFR2 and CXCR2 pathways. In the absence of immunosuppression, the microvasculature in rejecting allografts exhibited vascular complement deposition, diminished endothelial CD31 expression, and absent perfusion prior to the onset of fibroproliferation. Rejecting grafts with extensive endothelial cell injury were refractory to immunotherapy. After early microvascular loss, neovascularization was eventually observed in the membranous trachea, indicating a reestablishment of graft perfusion in established fibrosis. One implication of this study is that bronchial artery revascularization at the time of lung transplantation may decrease the risk of subsequent airway fibrosis.

Authors

Ashok N. Babu, Tomohiro Murakawa, Joshua M. Thurman, Edmund J. Miller, Peter M. Henson, Martin R. Zamora, Norbert F. Voelkel, Mark R. Nicolls

×

Figure 1

Loss of epithelium and subepithelial vessels after 8 days of acute rejection.

Options: View larger image (or click on image) Download as PowerPoint
Loss of epithelium and subepithelial vessels after 8 days of acute rejec...
(A) Radial section of syngeneic (B6→B6) tracheal graft 6 days after transplant demonstrating normal columnar epithelium. (B) Allogeneic (BALB/c→B6) graft with massive inflammatory cell infiltration of the subepithelium and epithelium 6 days following transplant. (C and D) Masson’s trichrome stain demonstrates subepithelial fibrosis and epithelial changes at 28 days in allografts as compared with normal histology in syngeneic grafts. (E) Coronal section of tracheal allograft at 8 days (n = 4) stained for MHC class I H-2Kd (BALB/c) demonstrates donor-type columnar epithelium in the graft without staining of recipient epithelium. (F) Coronal section of allograft at 12 days immunostained for MHC class I H-2Kd demonstrates replacement of columnar epithelium with flattened epithelium (short arrow). (G) Morphometric analysis of epithelial height demonstrates epithelial height loss between 8 days and 12 days. (H and I) Radial sections of tracheal allografts and corresponding vessel counts demonstrate loss of subepithelial vessels after 8 days of rejection. *P < 0.01 versus all other groups; n = 4–5 for all groups. allo, allogeneic; syn, syngeneic. Original magnification, ×4 (A, B, H, and I); ×20 (C and D).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts